PT33 Cost-Effectiveness of Pembrolizumab Plus Chemotherapy, With or Without Bevacizumab for the First-Line Treatment of PD-L1-Positive Patients With Persistent, Recurrent, or Metastatic Cervical Cancer in France
Abstract
Authors
I. Ray-Coquard P. Pautier D. Muston M.J. Monberg S. Swami O. Chaker L. Bensimon S. Lange M. Kulakova I. Durand Zaleski L. Marié